Circulating tumor DNA kinetics: A future tool for radiation therapy personalization in lung cancer? [0.03%]
循环肿瘤DNA的动力学：肺癌放射治疗个性化的一个未来工具？
Gerard M Walls,Bruna Pellini,Aadel A Chaudhuri
Gerard M Walls
Locally advanced non-small cell lung cancer (NSCLC) is a highly diverse disease in terms of its histology, staging and molecular biology, yet chemoradiation treatment paradigms are currently not individualized for these factors. Circulating...
Global requirements for manufacturing and validation of clinical grade extracellular vesicles [0.03%]
临床级细胞外囊泡制造和验证的全球要求
Abhimanyu Thakur,Deepika Rai
Abhimanyu Thakur
Extracellular vesicles (EVs) are nanovesicles released from different cell types from biofluids such as blood, urine, and cerebrospinal fluid. They vary in size and biomarkers, and their biogenesis pathways allow them to be divided into thr...
Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experience [0.03%]
ALK阳性非小细胞肺癌(NSCLC)患者的抗ALK自身抗体：单中心经验
Claudia Parisi,José Carlos Benitez,Hélène Lecourt et al.
Claudia Parisi et al.
Importance: Deregulation of anaplastic lymphoma kinase (ALK) occurs in 3-7% of advanced NSCLC mainly because of chromosomic rearrangements at the ALK locus. Next to its oncogenic function, ALK chimeric oncoprotein is a po...
Circulating tumor DNA fraction predicts residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer [0.03%]
循环肿瘤DNA分数预测新辅助化疗后三阴性乳腺癌的残留癌症负担
Naing Lin Shan,Billie Gould,Xiaohong Wang et al.
Naing Lin Shan et al.
Purpose: Pathologic response after preoperative/neoadjuvant chemotherapy (NAC) is a continuum that can range from complete pathologic response (pCR) to extensive residual disease (RD). We hypothesized that post-NAC plasma...
Development and validation of a novel combinational index of liquid biopsy biomarker for longitudinal lung cancer patient management [0.03%]
液体活检生物标志物新型组合指数的开发和验证，用于肺癌患者的纵向管理
Min-Yi Liao,Yun-Jie Hao,Ching-Shan Luo et al.
Min-Yi Liao et al.
Objectives: Many cancer biomarkers such as the circulating tumor cells/microemboli (CTCs/CTM) have been reported significant associations with clinical outcomes. However, different biomarkers have different sensitivities ...
A revolutionary era in advancing precision immuno-oncology; role of circulating tumor cells [0.03%]
推动精准肿瘤免疫治疗的新纪元；循环肿瘤细胞的作用
Nazila Bahmaie,Ozen Ozensoy Guler,Ender Simsek
Nazila Bahmaie
Despite a substantial progress in the development of strategies against cancer, cancer still remains a major global health issue due to a high recurrence rate, and severe side effects, leading basic medical scientists and clinical specialis...
Muhammad Izhar,Ziyad Ahmad,Manahil Moazzam et al.
Muhammad Izhar et al.
Cerebrospinal fluid (CSF) is a promising source of molecular biomarkers in the detection and monitoring of brain malignancies. Unlike peripheral blood, where biomarker detection is hindered by the blood-brain barrier and the complex nature ...
Global landscape of liquid biopsy research: Regional contributions and disparities [0.03%]
液体活检研究的全球格局：区域贡献和差异
Siddig Ibrahim Abdelwahab,Abdullah Farasani,Hassan Ahmad Alfaifi et al.
Siddig Ibrahim Abdelwahab et al.
Objective: Liquid biopsy has revolutionized cancer research, diagnosis, and personalized treatment. This study aimed to explore regional contributions and disparities in this rapidly advancing field. ...
Comprehensive analysis of plasma methylome reveals distinct patterns of methylation changes between responders and non-responders to neoadjuvant chemotherapy in breast cancer [0.03%]
血浆甲基化的综合分析揭示了乳腺癌新辅助化疗反应者和非反应者的甲基化变化模式不同
Francesco Ravera,Martina Dameri,Pier Vitale Nuzzo et al.
Francesco Ravera et al.
The potential of cell-free DNA (cfDNA) methylation profiling in oncology is increasingly recognized for its ability to offer a comprehensive assessment of tumor biology. In this report, we explore the plasma methylome dynamics in patients w...
Liquid biopsy, big data and artificial intelligence as a new global clinical trial model in targeted therapy [0.03%]
液体活检，大数据及人工智能作为靶向治疗新的全球临床试验模型
Albert Abad,Joana Vidal,Laura Layos et al.
Albert Abad et al.
To this day, the phase III trial continues to be, as it was more than 60 years ago, the standard for the incorporation of new treatments in oncology. We currently have new tools such as NGS, Liquid Biopsy (LB), Big Data (BD) and Artificial ...